Brokers Set Expectations for Atyr PHARMA FY2025 Earnings

Atyr PHARMA INC (NASDAQ:ATYR) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Atyr PHARMA in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will earn ($0.87) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share.

A number of other brokerages have also issued reports on ATYR. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Wells Fargo & Company initiated coverage on shares of Atyr PHARMA in a report on Friday, October 4th. They set an “overweight” rating and a $17.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $19.25.

Atyr PHARMA Stock Performance

Shares of NASDAQ:ATYR opened at $3.63 on Wednesday. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.22. The stock’s fifty day moving average is $3.40. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01).

Institutional Trading of Atyr PHARMA

An institutional investor recently raised its position in Atyr PHARMA stock. JPMorgan Chase & Co. raised its holdings in Atyr PHARMA INC (NASDAQ:ATYR) by 52.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,440 shares of the company’s stock after purchasing an additional 10,754 shares during the period. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 at the end of the most recent quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.